Source BioScience supports Cervical Cancer Awareness Week
To mark Cervical Cancer Awareness Week, Source BioScience, providers of cervical cancer screening technology, joins the National Health Service Cervical Screening Programme (‘NHSCSP’) and charities, such as Jo’s Cervical Cancer Trust, Michelle Henderson Cervical Cancer Trust and MacMillan Cancer Support, in calling for all eligible women to attend their cervical screening test.
The UK leads the way by having the best organised cervical cancer screening programme in the world and sets the standard for other countries in the early detection and treatment of cervical cancer. However, even with this premier standard of care, 1 in 5 women in the UK do not respond to their cervical screening invitation and there are still over 2,900 women in the UK diagnosed with cervical cancer every year.
It is therefore an important message to raise both public awareness that cervical cancer can be prevented by early screening and detection; and to urge women to attend for potentially life saving screening.
Wilma Anderson, Business Manager at Source BioScience commented, “As a previous employee of the NHS, and with 11 years’ experience looking down the microscope at cervical slides, I know this test can pick up small changes in the cells that, if untreated, may progress into cervical disease. All women should accept their invitation for testing when they receive it. It can and does save lives as this disease can be treated if caught early.”
Source BioScience has been supplying the BD SurePath™ screening technology to the NHSCSP since 2002 and now provides approximately 50% of all cervical cancer screening kits used by the NHS in England and Wales. Last year, approximately two million samples were analysed using the BD SurePath™ platform. Source BioScience has also been working closely with the NHSCSP to introduce automated imaging of cervical slides using the BD FocalPoint™ technology. This can reduce by up to 25% the number of tests which require manual screening, thereby speeding up the turnaround time for patients to receive their results. To date seven systems have been adopted by five NHS Trusts with further uptake expected during 2013.
Nick Ash, CEO of Source BioScience, added: “There is a major benefit to women in attending their routine cervical screening test and we recognise the excellent work of organisations such as Jo’s Cervical Cancer Trust and the NHSCSP in raising awareness of this disease and need for testing. The action and activities of these organisations help to ensure this disease can be caught early and treated, and has significantly reduced the incidence of cervical cancer in the UK.”
For further information, please contact:
Source BioScience plc
Business Manager, Healthcare
Tel: +44 (0) 781 132 6412
College Hill (PR Agency to Source BioScience)
Melanie Toyne-Sewell/Stefanie Bacher
Tel: +44 (0)207 457 2020
Mob: +44 (0)7992 693760